BiotechTube
Home/Alpha Fusion/Nao Fujioka, M.S., R.Ph.
NF

Nao Fujioka, M.S., R.Ph.

CEO, Representative Director

Alpha Fusion

Therapeutic Areas

Oncology

Alpha Fusion Pipeline

DrugIndicationPhase
af-001 (TAH-1005)Thyroid Cancer (Radioiodine-Refractory)Phase 1
af-001Thyroid Cancer (Radioiodine-Naïve)Phase 1
af-002 (PSW-1025)Prostate Cancer (Refractory)IND-enabling
af-003Pan-CancerIND-enabling
Tanabe-Veneno ProgramUndisclosedExploratory
In-house ProgramUndisclosedExploratory

Leadership Team at Alpha Fusion

YT
Yuichi Tomura, Ph.D., R.Ph.
Head of R&D
NI
Nobuo Ishida, R.Ph.
Head of Clinical Development
TN
Takanori Nakano, Ph.D.
Co-founder, Board Director
TN
Tomoya Nagata, M.S., R.Ph.
Co-founder, Board Director
View full Alpha Fusion profile